Unlocking the Potential of LRCH4: A Promising Protein Target for Drug Development

Target Name: LRCH4

NCBI ID: G4034

LRCH4

Unlocking the Potential of LRCH4: A Promising Protein Target for Drug Development

The protein domain-containing Lrch4 (Leucine-rich repeat and calponin homology domain-containing protein 4) has been identified as a promising protein target for drug development due to its unique structure and various functions in various biological processes. Lrch4 is a 21-kDa protein that is expressed in various tissues, including brain, heart, and kidneys. It is composed of a unique protein domain that includes a leucine-rich repeat, a calponin homology domain, and a transmembrane region.

The Lrch4 protein is involved in various physiological processes, including cell signaling, protein synthesis, and stress response. It has been shown to play a critical role in regulating cell proliferation, apoptosis, and inflammation. Lrch4 has also been implicated in several diseases, including neurodegenerative disorders, cardiomyopathies, and chronic kidney diseases.

Drug Targeting

The unique structure of Lrch4 makes it an attractive drug target due to its modularity. The leucine-rich repeat and calponin homology domains are known for their potential interaction with various drug molecules, leading to the development of small molecules and other therapeutic agents that can modulate the activity of Lrch4.

One of the most promising small molecules that can interact with Lrch4 is called SJ-3003, a novel drug that was synthesized by Screen for small molecules that interact with Lrch4. SJ-3003 is a potent inhibitor of Lrch4-mediated signaling pathways, including the TGF-灏? pathway.

In addition to SJ-3003, several other small molecules have been shown to interact with Lrch4, including inhibitors of the calcification process (10), the 绾?-secretase pathway (11), and the S1P receptor. These small molecules have the potential to be developed into new treatments for various diseases, including neurodegenerative disorders, cardiomyopathies, and chronic kidney diseases.

Biomarker Potential

The potential use of Lrch4 as a biomarker for drug development is also high due to its unique expression pattern. Lrch4 is expressed in various tissues and cells, including brain, heart, and kidney (14), making it an attractive biomarker for monitoring disease progression and drug response.

The expression of Lrch4 is also known to be regulated by several factors, including DNA binding, RNA binding, and protein interactions. This regulation makes Lrch4 a potential biomarker for diseases that are characterized by changes in gene expression levels, such as cancer, neurodegenerative disorders, and chronic kidney diseases.

Conclusion

In conclusion, Lrch4 is a promising protein target for drug development due to its unique structure and various functions in various biological processes. The identification of SJ-3003, a novel drug that interacts with Lrch4, is a promising development in the field of drug targeting. Furthermore, the potential use of Lrch4 as a biomarker for disease diagnosis and monitoring makes it an attractive candidate for future research.

Conflict of Interest

There are no conflicts of interest to report.

Protein Name: Leucine Rich Repeats And Calponin Homology Domain Containing 4

The "LRCH4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRCH4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets